Počet záznamů: 1  

Aurora kinase inhibitors: Progress towards the clinic

  1. 1.
    SYSNO ASEP0377543
    Druh ASEPJ - Článek v odborném periodiku
    Zařazení RIVJ - Článek v odborném periodiku
    Poddruh JČlánek ve WOS
    NázevAurora kinase inhibitors: Progress towards the clinic
    Tvůrce(i) Kollareddy, M. (CZ)
    Zheleva, D. (GB)
    Dzubak, P. (CZ)
    Brahmkshatriya, Pathik (UOCHB-X)
    Lepšík, Martin (UOCHB-X) RID
    Hajduch, M. (CZ)
    Celkový počet autorů6
    Zdroj.dok.Investigational New Drugs - ISSN 0167-6997
    Roč. 30, č. 6 (2012), s. 2411-2432
    Poč.str.22 s.
    Jazyk dok.eng - angličtina
    Země vyd.US - Spojené státy americké
    Klíč. slovaAurora kinases ; cancer ; inhibitors
    Vědní obor RIVCF - Fyzikální chemie a teoretická chemie
    CEZAV0Z40550506 - UOCHB-X (2005-2011)
    UT WOS000310470100036
    DOI10.1007/s10637-012-9798-6
    AnotaceThe Aurora kinases (serine/threonine kinases) were discovered in 1995 during studies of mutant alleles associated with abnormal spindle pole formation in Drosophila melanogaster. They soon became the focus of much attention because of their importance in human biology and association with cancer. Aurora kinases are essential for cell division and are primarily active during mitosis. Following their identification as potential targets for cancer chemotherapy, many Aurora kinase inhibitors have been discovered and developed. Currently, there are about 30 Aurora kinase inhibitors in different stages of pre-clinical and clinical development. This review summarizes the characteristics and status of Aurora kinase inhibitors in preclinical, Phase I, and Phase II clinical studies, with particular emphasis on the mechanisms of action and resistance to these promising anticancer agents.
    PracovištěÚstav organické chemie a biochemie
    KontaktJana Procházková, janap@uochb.cas.cz, Tel.: 220 183 418 ; Viktorie Chládková, viktorie.chladkova@uochb.cas.cz, Tel.: 232 002 434
    Rok sběru2013